Cell & Gene: The Podcast
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
Jan 30, 2025
Helen Sabzevari, Ph.D., President and CEO of Precigen, shares insights on innovative adenovirus-based therapies. She discusses the promising use of gorilla adenovectors, which enhance the delivery of large genetic payloads for effective gene therapies. Sabzevari reveals exciting results from Precigen's recent BLA submission, with over 50% of patients achieving Complete Response in pivotal studies. She also highlights the company's groundbreaking work in treating recurrent respiratory papillomatosis and the potential for broad applications in immuno-oncology and beyond.
26:49
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Precigen's use of gorilla adenovirus vectors enables the delivery of larger genetic payloads, enhancing the development of effective gene therapies.
- The recent BLA submission for PRGN-2012 marks a pivotal shift towards commercialization, promising FDA approval for a groundbreaking treatment for RRP.
Deep dives
Innovative Developments in Gene Therapy
Presogen is focused on advancing gene therapy through its unique platforms: the Gorilla Adenoprovector platform and the UltraCarty platform, with special emphasis on the PRGN 2012 program targeting recurrent respiratory papillomatosis (RRP). This represents a significant step as it seeks to obtain the first FDA-approved treatment for adults with RRP. The regulatory submission is a crucial milestone, marking a transition from research and development to commercialization, which holds great promise for patients suffering from this condition. By leveraging innovative approaches in gene therapy, Presogen aims to address unmet medical needs in immuno-oncology and other areas.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
